The effects of sertraline on blood lipids, glucose, insulin and HBA1C levels: A prospective clinical trial on depressive patients

Journal of Research in Medical Sciences

Volumn 16, Issue 12, 2011, Pages 1525-1531

  Kesim, Murat ^a   Tiryaki, Ahmet ^a   Kadioglu, Mine ^a   Muci, Efnan ^a   Kalyoncu, Nuri Ihsan ^a   Yaris, Ersin ^a  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Glucose; HbA1C; Insulin; Lipid; Sertraline

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SERTRALINE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; PHYSICAL EXAMINATION; PROSPECTIVE STUDY; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT INDICATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84855803779     PISSN: 17351995     EISSN: 17357136     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rubin RR, Gaussoin SA, Peyrot M, DiLillo V, Miller K, Wadden TA, et al. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia 2010; 53(8): 1581-9.
2. Whang W, Shimbo D, Kronish IM, Duvall WL, Julien H, Iyer P, et al. Depressive symptoms and all-cause mortality in unstable angina pectoris (from the Coronary Psychosocial Evaluation Studies [COPES]). Am J Cardiol 2010; 106(8): 1104-7.
3. Davidson KW, Korin MR. Depression and cardiovascular disease: selected findings, controversies, and clinical implications from 2009. Cleve Clin J Med 2010; 77(Suppl 3): S20-S26.
4. Glassman A. Depression and cardiovascular disease. Pharmacopsychiatry 2008; 41(6): 221-5.
5. Iosifescu DV, Clementi-Craven N, Fraguas R, Papakostas GI, Petersen T, Alpert JE, et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med 2005; 67(5): 703-6.
6. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, Van GL. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 1996; 4(4): 391-6.
7. Ghaeli P, Shahsavand E, Mesbahi M, Kamkar MZ, Sadeghi M, Dashti-Khavidaki S. Comparing the effects of 8week treatment with fluoxetine and imipramine on fasting blood glucose of patients with major depressive disorder. J Clin Psychopharmacol 2004; 24(4): 386-8.
8. Derijks HJ, Janknegt R, Heerdink ER, De Koning FH, Krekels MM, Looij BJ, et al. Influence of antidepressant use on glycemic control in patients with diabetes mellitus: an open-label comparative study. J Clin Psychopharmacol 2009; 29(4): 405-8.
9. Raeder MB, Bjelland I, Emil VS, Steen VM. Obesity, dyslipidemia, and diabetes with selective serotonin reuptake inhibitors: the Hordaland Health Study. J Clin Psychiatry 2006; 67(12): 1974-82.
10. Wei F, Crain AL, Whitebird RR, Godlevsky OV, O'Connor PJ. Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study. CNS Drugs 2009; 23(10): 857-65.
11. Teitelbaum M. Severe hypertriglyceridemia secondary to venlafaxine and fluoxetine. Psychosomatics 2001; 42(5): 440-1.
12. Herran A, Ramirez ML, Carrera M, Garcia-Unzueta MT, Sierra-Biddle D, Rodriguez-Cabo B, et al. Panic disorder, treatment with selective serotonin reuptake inhibitors, and cholesterol levels. J Clin Psychopharmacol 2006; 26(5): 538-40.
13. Erenmemisoglu A, Ozdogan UK, Saraymen R, Tutus A. Effect of some antidepressants on glycaemia and insulin levels of normoglycaemic and alloxan-induced hyperglycaemic mice. J Pharm Pharmacol 1999; 51(6): 741-3.
14. Gomez R, Huber J, Tombini G, Barros HMT. Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Brazilian Journal of Medical and Biological Research 2001; 34(1): 57-64.
15. Gomez R, Huber J, Lhullier F, Barros HM. Plasma insulin levels are increased by sertraline in rats under oral glucose overload. Braz J Med Biol Res 2001; 34(12): 1569-72.
16. Pollak PT, Mukherjee SD, Fraser AD. Sertraline-induced hypoglycemia. Ann Pharmacother 2001; 35(11): 1371-4.
17. Sansone RA, Sansone LA. Sertraline-induced hyperglycemia: case report. Int J Psychiatry Med 2003; 33(1): 103-5.
18. Paulmann N, Grohmann M, Voigt JP, Bert B, Vowinckel J, Bader M, et al. Intracellular serotonin modulates insulin secretion from pancreatic beta-cells by protein serotonylation. PLoS Biol 2009; 7(10): e1000229.
19. Lautt WW, Ming Z, Legare DJ. Attenuation of ageand sucrose-induced insulin resistance and syndrome X by a synergistic antioxidant cocktail: the AMIS syndrome and HISS hypothesis. Can J Physiol Pharmacol 2010; 88(3): 313-23.
20. Sadri P, Reid MA, Afonso RA, Schafer J, Legare DJ, Paula MM, et al. Meal-induced insulin sensitization in conscious and anaesthetized rat models comparing liquid mixed meal with glucose and sucrose. Br J Nutr 2006; 95(2): 288-95.
21. Patarrao RS, Lautt WW, Afonso RA, Ribeiro RT, Guarino MP, Fernandes AB, et al. Meal-induced insulin sensitization and its parasympathetic regulation in humans. Can J Physiol Pharmacol 2008; 86(12): 880-8.